Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31397381 | 0.91 | MCHR1 (0.41) | MCHR1KCNH2LRRK2KHKHRH4 | |
| SCHEMBL30274029 | 0.88 | GRM5 (0.40) | MCHR1HRH4GRM5PIK3CAPRKDC | |
| SCHEMBL31397327 | 0.87 | GRM5 (0.37) | MCHR1LRRK2HRH4GRM5PIK3CA | |
| SCHEMBL31397300 | 0.85 | GRM5 (0.36) | MCHR1KCNH2LRRK2HRH4GRM5 | |
| SCHEMBL30273826 | 0.85 | CYP11B2 (0.39) | LRRK2GRM5PRMT5 | |
| SCHEMBL23541153 | 0.85 | LRRK2 (0.40) | MCHR1KCNH2LRRK2HRH4GRM5 | |
| SCHEMBL31396978 | 0.84 | TMEM97 (0.36) | MCHR1KCNH2LRRK2HRH4GRM5 | |
| SCHEMBL31397183 | 0.84 | KHK (0.43) | MCHR1KCNH2KHKHRH4GRM5 | |
| SCHEMBL31397270 | 0.84 | MCHR1 (0.37) | MCHR1KCNH2LRRK2HRH4GRM5 | |
| SCHEMBL31397140 | 0.84 | KHK (0.43) | MCHR1KCNH2KHKHRH4GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | MCHR1 868/4885KCNH2 4876/4885LRRK2 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.